Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Treprostinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 12/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 3/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 3/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 6/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Treprostinil SCHEMBL11914201 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349622 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL9418778 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL14732787 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL11953002 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349618 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL24243789 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL22282429 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL21530472 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL16342147 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332175-A1 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | LIQUIDIA TECHNOLOGIES, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12390475-B2 | Dry powder treprostinil for the treatment of pulmonary hypertension | LIQUIDIA TECHNOLOGIES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250170081-A1 | TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION | INVOX BELGIUM NV (BE) | 2025-05-29 | — | — | US | disclosed |
| US-20240400487-A1 | SALTS OF TREPROSTINIL | UNITED THERAPEUTICS CORPORATION (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102610-B2 | Treprostinil salt | ELI LILLY AND COMPANY (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240262778-A1 | SALTS OF TREPROSTINIL | UNITED THERAPEUTICS CORPORATION (US) | 2024-08-08 | — | — | US | disclosed |
| EP-3853200-B1 | ERBUMINE SALT OF TREPROSTINIL | LILLY CO ELI (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230346799-A1 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | LIQUIDIA TECHNOLOGIES, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-11744836-B2 | Dry powder treprostinil for the treatment of pulmonary hypertension | LIQUIDIA TECHNOLOGIES, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744835-B2 | Dry powder treprostinil for the treatment of pulmonary hypertension | LIQUIDIA TECHNOLOGIES, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-2300408-B1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL MONOHYDRATE AND ITS USE FOR STORAGE AND SHIPPING | UNITED THERAPEUTICS CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3002274-A1 | TREPROSTINIL MONOHYDRATE | United Therapeutics Corporation (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150315114-A1 | Methods of Synthesizing a Prostacyclin Analog | CAYMAN CHEMICAL COMPANY INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-20150266801-A1 | SALTS OF TREPROSTINIL | UNITED THERAPEUTICS CORPORATION (US) | 2015-09-24 | — | — | US | disclosed |
| US-20140275616-A1 | SALTS OF TREPROSTINIL | UNITED THERAPEUTICS CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130317245-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF | CHIROGATE INTERNATIONAL INC. (TW) | 2013-11-28 | — | — | US | disclosed |
| US-8524939-B2 | Intermediates for the synthesis of benzindene prostaglandins and preparations thereof | CHIROGATE INTERNATIONAL INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| US-20130053581-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF | CHIROGATE INTERNATIONAL INC. | 2013-02-28 | — | — | US | disclosed |
| US-8350079-B2 | Treprostinil formulation | UNITED THERAPEUTICS CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090281189-A1 | TREPROSTINIL FORMULATION | UNITED THEREPEUTICS CORPORATION | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170081-A1 | TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION | PTGIR, AGTR2, PTGIS | PTGIR 1/4885PTGER2 14/4885PTGER1 13/4885 |
| US-20140275616-A1 | SALTS OF TREPROSTINIL | TREH, TTPA, TYMP | PTGIR 21/4885PTGER2 78/4885PTGER1 29/4885 |
| US-12390475-B2 | Dry powder treprostinil for the treatment of pulmonary hypertension | PTGIR, PTGIS, TSLP | PTGIR 1/4885PTGER2 4/4885PTGER1 7/4885 |
| US-20150266801-A1 | SALTS OF TREPROSTINIL | TREH, TTPA, TYMP | PTGIR 21/4885PTGER2 78/4885PTGER1 29/4885 |
| US-20130053581-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF | PTGIS, PTGES, PTGS1 | PTGIR 6/4885PTGER2 12/4885PTGER1 7/4885 |
| US-20150315114-A1 | Methods of Synthesizing a Prostacyclin Analog | PTGIS, CYP11B2, CYP11B1 | PTGIR 5/4885PTGER2 20/4885PTGER1 4/4885 |
| US-20250332175-A1 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | PTGIR, PTGIS, TSLP | PTGIR 1/4885PTGER2 4/4885PTGER1 7/4885 |
| US-20090281189-A1 | TREPROSTINIL FORMULATION | TREH, TTPA, PTGFR | PTGIR 8/4885PTGER2 28/4885PTGER1 13/4885 |
| US-11744835-B2 | Dry powder treprostinil for the treatment of pulmonary hypertension | PTGIR, PTGIS, TSLP | PTGIR 1/4885PTGER2 4/4885PTGER1 7/4885 |
| US-11744836-B2 | Dry powder treprostinil for the treatment of pulmonary hypertension | PTGIR, PTGIS, TSLP | PTGIR 1/4885PTGER2 4/4885PTGER1 7/4885 |
| US-20230346799-A1 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | PTGIR, PTGIS, TSLP | PTGIR 1/4885PTGER2 4/4885PTGER1 7/4885 |
| US-20240400487-A1 | SALTS OF TREPROSTINIL | TREH, TTPA, TYMP | PTGIR 21/4885PTGER2 78/4885PTGER1 29/4885 |
| US-12102610-B2 | Treprostinil salt | TREH, DCTPP1, THPO | PTGIR 13/4885PTGER2 79/4885PTGER1 31/4885 |
| US-20130317245-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF | PTGIS, PTGES, PTGS1 | PTGIR 6/4885PTGER2 12/4885PTGER1 7/4885 |
| US-20240262778-A1 | SALTS OF TREPROSTINIL | TREH, TTPA, TYMP | PTGIR 21/4885PTGER2 78/4885PTGER1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.